文献速递白血病

美国药品价格、廉价仿制伊马替尼的可及性、新药获批及上市后研究对慢性髓性白血病治疗的影响

The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA.
PubMed 文献 · Lancet Haematol · 2022-09-26

本文综述了过去5年影响慢性髓性白血病一线及后续治疗策略的研究与市场动态,包括廉价仿制伊马替尼的可及、低于批准剂量的TKI有效且毒性更低、剂量调整的泊那替尼有效且更安全,以及2021年阿西米尼获批三线治疗。作者认为廉价仿制伊马替尼应使全球所有患者获得终身供应,减量二代TKI可能更具一线吸引力,泊那替尼是二代TKI耐药或944C→T突变患者的优选,阿西米尼需更大样本和更长随访评估。

要点

  • 廉价仿制伊马替尼可及后,全球所有慢性髓性白血病患者应能获得终身供应。
  • 低于批准剂量的TKI有效且毒性更低,减量二代TKI可能更具一线治疗吸引力。
  • 剂量调整的泊那替尼长期随访显示更好疗效和安全性,是二代TKI耐药或944C→T突变患者的优选。

核心结论

  • 廉价仿制伊马替尼可及后,全球所有慢性髓性白血病患者应能获得终身供应。
  • 减量二代TKI毒性更低且比伊马替尼更快达到深度分子学反应,可能使其作为一线治疗更具吸引力。
  • 泊那替尼是二代TKI耐药或944C→T(Thr315Ile)突变BCR-ABL1慢性髓性白血病患者的优选治疗。
  • 阿西米尼需在更大样本和更长随访中评估其对比泊那替尼的疗效、安全性和生存数据。

研究设计与样本

  • 本文为综述,检索范围未在原文中报告。

主要发现

  • 过去5年出现廉价仿制伊马替尼的可及性增加。
  • 研究显示低于批准剂量的TKI有效且毒性更低。
  • 剂量调整的泊那替尼在降低剂量下有效且比批准剂量显著更安全,长期随访显示更好疗效和安全性。
  • 2021年阿西米尼获批作为三线治疗。

关键数值与推荐

  • 泊那替尼为二代TKI耐药或944C→T(Thr315Ile)突变BCR-ABL1患者的优选治疗。
  • 阿西米尼对比泊那替尼的疗效、安全性和生存数据需更大样本和更长随访评估。
  • 二代TKI一线耐药后三代TKI作为二线治疗的作用需评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 阿西米尼研究需更大样本量和比既往更长的随访。
  • 二代TKI一线耐药后三代TKI作为二线治疗的作用需评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several research and market developments in the past 5 years could influence front-line and subsequent-line strategies in chronic myeloid leukaemia. These developments include the increased availability of effective and safe generic imatinib at affordable prices, studies showing that doses of tyrosine kinase inhibitors (TKIs) lower than the approved dose are effective and less toxic, studies showing that dose-adjusted ponatinib therapy at a reduced dose is effective and substantially safer than approved doses, and the approval of asciminib as third-line therapy in 2021. With the availability of an affordable generic imatinib, all patients with chronic myeloid leukaemia globally should be able to access a lifetime supply. The availability of reduced-dose schedules of generic second-generation TKIs, which are less toxic and produce faster deep molecular response than imatinib, might make them more appealing to use as front-line therapy. In the subsequent-line setting, the role of different TKIs as second, third, and later lines of therapy depends on the evolving front-line use. Dose-adjusted ponatinib schedules have shown better efficacy and safety with long-term follow-up. Ponatinib is the favoured therapy for patients with second-generation-TKI resistance or chronic myeloid leukaemia with 944C→T (Thr315Ile)-mutated BCR-ABL1. Studies of asciminib are needed in larger numbers of patients and with longer follow-up than has been done previously to better assess its comparative efficacy, safety, and survival data (vs ponatinib). The role of third-generation TKIs as second-line therapy following front-line resistance to second-generation TKIs needs to be evaluated. New and mature data with TKI therapy in chronic myeloid leukaemia are producing observations that encourage continuous discussion of the optimal treatment recommendations and frameworks in chronic myeloid leukaemia.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Kantarjian H, Paul S, Thakkar J, et al. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol. 2022. PMID: 36174582. doi:10.1016/S2352-3026(22)00246-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。